Core Viewpoint - The Schall Law Firm is investigating PTC Therapeutics, Inc. for potential violations of securities laws related to misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether PTC issued false or misleading statements regarding the results of the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Huntington's disease patients [2]. - PTC announced that the study met its primary endpoint of reducing blood Huntingtin (HTT) protein levels with a significant p-value of less than 0.0001 at Week 12, along with favorable safety and tolerability [2]. - Analysts suggest that a Phase 3 study is necessary to confirm if the treatment effectively slows the progression of Huntington's disease, leading to a significant drop in PTC's share price by over 18.6% on the announcement day [2].

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 5, 2025 ...

Core Viewpoint - PTC Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following the announcement of Phase 2 study results for its treatment of Huntington's disease, which led to a significant drop in stock price [1][2][3]. Group 1: Company Developments - PTC announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease patients, achieving its primary endpoint of reducing blood Huntingtin protein levels with a p-value of less than 0.0001 at Week 12 [2]. - Despite meeting the primary endpoint, analysts suggest that a Phase 3 study may be necessary to confirm the treatment's efficacy in slowing the progression of Huntington's disease [2]. Group 2: Market Reaction - Following the announcement of the study results, PTC's stock price fell by $9.30 per share, representing an 18.62% decline, closing at $40.65 per share on May 5, 2025 [3].

PTC Therapeutics, Inc. PTCT on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients.Huntington’s disease is a progressive neurodegenerative disorder caused by mutation of the huntingtin (HTT) gene, leading to the breakdown of brain cells. It is characterized by uncontrolled movements (chorea), cognitive decline, and psychiatric disturbances.The study met its primary endpoint of reduction in blood Huntingtin (HTT) protein leve ...